Moreover, reactivation of mutant TP53 combined with olaparib resulted in more efficient inhibition of tumour growth in the preclinical model of triple negative breast cancer with a TP53 mutation (33). This evidence concerns the gene TP53 and triple-negative breast carcinoma.